Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20

TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
October 23, 2018 08:00 ET | Source: VBL Therapeutics

Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033

TEL AVIV, Israel, Oct. 23, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), today announced the issuance by the European Patent Office (EPO) of Patent No. 2908865, a composition of matter...
October 11, 2018 07:00 ET | Source: VBL Therapeutics

Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis

TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation,”...
September 17, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at Upcoming Conferences in October

TEL AVIV, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
August 30, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis

These data, together with positive preclinical NASH data previously presented, support the potential of VBL’s lecinoxoid pipelineRecently granted US patent provides patent protection for lecinoxoids...
August 16, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Second Quarter 2018 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today VBL is well capitalized, cash sufficient for more than 3 years, beyond key inflection pointsVBL continues development of VB-111 for Ovarian...
August 01, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16

TEL AVIV, Israel, Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
July 10, 2018 08:00 ET | Source: VBL Therapeutics

Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy

Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer TEL AVIV, Israel, July 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced...
June 27, 2018 16:01 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering

TEL AVIV, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
June 26, 2018 08:57 ET | Source: VBL Therapeutics

VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market

TEL AVIV, Israel, June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...